Correlation of EGFR, pEGFR and p16INK4 expressions and high risk HPV infection in HIV/AIDS-related squamous cell carcinoma of conjunctiva by Mwololo, A et al.
Mwololo et al. Infectious Agents and Cancer 2014, 9:7
http://www.infectagentscancer.com/content/9/1/7RESEARCH ARTICLE Open AccessCorrelation of EGFR, pEGFR and p16INK4 expressions
and high risk HPV infection in HIV/AIDS-related
squamous cell carcinoma of conjunctiva
Anthony Mwololo1, Joshua Nyagol1,3*, Emily Rogena1, Willis Ochuk1, Mary Kimani1, Noel Onyango1,
Lorenzo Pacenti2, Rosa Santopietro2, Lorenzo Leoncini2 and Walter Mwanda1Abstract
Background: Squamous cell carcinoma of conjunctiva has increased tenfold in the era of HIV/AIDS. The disease
pattern has also changed in Africa, affecting young persons, with peak age-specific incidence of 30-39 years, similar
to that of Kaposi sarcoma, a well known HIV/AIDS defining neoplasm. In addition, the disease has assumed more
aggressive clinical course. The contributing role of exposure to high risk HPV in the development of SCCC is still
emerging.
Objective: The present study aimed to investigate if immunohistochemical expressions of EGFR, pEGFR and p16,
could predict infection with high risk HPV in HIV-related SCCC.
Methods: FFPE tissue blocks of fifty-eight cases diagnosed on hematoxylin and eosin with SCCC between 2005-2011,
and subsequently confirmed from medical records to be HIV positive at the department of human pathology,
UoN/KNH, were used for the study. Immunohistochemistry was performed to assess the expressions of p16INK4A,
EGFR and pEGFR. This was followed with semi-nested PCR based detection and sequencing of HPV genotypes. The
sequences were compared with the GenBank database, and data analyzed for significant statistical correlations
using SPSS 16.0. Ethical approval to conduct the study was obtained from KNH-ERC.
Results: Out of the fifty-eight cases of SCCC analyzed, twenty-nine (50%) had well differentiated (grade 1), twenty
one (36.2%) moderately differentiated (grade 2) while eight (13.8%) had poorly differentiated (grade 3) tumours.
Immunohistochemistry assay was done in all the fifty eight studied cases, of which thirty nine cases (67.2%) were
positive for p16INK4A staining, forty eight cases (82.8%) for EGFR and fifty one cases (87.9%) showed positivity for
p-EGFR. HPV DNA was detected in 4 out of 40 SCCC cases (10%) in which PCR was performed, with HPV16 being
the only HPV sub-type detected. Significant statistical association was found between HPV detection and p16INK4
(p=0.000, at 99% C.I) and EGFR (p=0.028, at 95% C.I) expressions, but not pEGFR. In addition, the expressions of
these biomarkers did not show any significant association with tumor grades.
Conclusion: This study points to an association of high risk HPV with over expressions of p16INK4A and EGFR
proteins in AIDS-associated SCCC.
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Squamous cell carcinoma of conjunctiva (SCCC) is a rare,
slow-growing tumor of a spectrum of conditions collect-
ively known as ‘ocular surface epithelial dysplasias’. These
range from benign dysplasias, to carcinoma in situ and ul-
timately to invasive carcinoma [1,2]. It is also considered
the most common neoplasm of the conjunctiva, normally
affecting elderly men of around 70 years [3,4]. The etiology
of SCCC has been previously viewed as multifactorial, with
ultraviolet light implicated as the major risk factor for these
tumors, and more common in equatorial Africa than in
Europe or North America [5].
In Africa, however, the incidence of SCCC has risen
rapidly in the recent past, with the peak age-specific
incidence reported to be 30-39 years, similar to that of
HIV/AIDS pandemics in the tropics. The disease is also
more aggressive, with a mean history of three months
at presentation [4,5]. An association between human
immunodeficiency virus (HIV) infection and squamous
cell carcinoma of the conjunctiva was first reported in
the mid-1990s. Subsequently, other studies also reported
that since the advent of HIV/AIDS in 1980s, the number
of patients presenting with SCCC had been increasing
exponentially [6-8]. In 1995, Ateenyi-Agaba observed that
a high incidence of these tumors in Uganda appeared
to be related to HIV infection [9]. Parallel studies by
Waddell and colleagues also suggested that HIV infection
is strongly associated with an increase in the incidence of
conjunctival carcinoma in Africa [10].
Although the natural history of the SCCC appears to
be unique in this region of the world with etiologic
mechanism unclear and therapeutic options limited, im-
munosuppression from HIV has been thought to facilitate
the activity of other infective agents that induce the carcin-
oma. This has been supported by many studies that have
documented the presence of high risk HPV genotypes 16
and 18 DNA in a proportion of SCCC [11]. The oncopro-
teins E6 and E7 encoded by the high risk HPV genotypes
are well documented to play a critical role in pathogenesis
of anogenital carcinomas by deregulation of cell cycle
control proteins p53 and pRb2/p130, respectively [12-18].
Another cell cycle regulatory protein whose increased
expression is reported to be predictive of, and an inde-
pendent prognostic marker in high risk HPV infection
is p16INK4A [19-22]. However, in our previous study to
investigate the roles played by HIV-1 Tat and high risk
HPV E6/E7 proteins in promoting carcinogenesis in
cervical cancers, expressions of p16INK4A was found to be
reduced in HIV-related squamous cell carcinoma of the
uterine cervix, a correlation which has also been supported
by other studies [23,24].
Few authors have also proposed involvement of high
risk HPVs in the oncogenesis through altered expression of
other key molecules involved in tyrosine kinase pathways,in which inverse expressions of epidermal growth factor
receptor (EGFR) and its phosphorylated form (pEGFR)
have been reported to contribute to the pathogenesis of
HIV/AIDS–associated SCCC, and correlates with poor
prognosis [25-27]. Altogether, expressions of p16INKA4,
EGFR and its phosphorylated form pEGFR have been
proposed to reflect infection with high risk HPV in
squamous cell carcinoma of conjunctiva. However, HPV
detection in conjunctival neoplasm has been largely contro-
versial, and the pathogenic mechanism not well elucidated.
Some of these studies have reported a heterogeneous preva-
lence of high-risk HPV genotypes, suggesting that only a
subset of cases can be attributed to these viruses. This vari-
ation in the reported HPV infection rates in conjunctival
squamous cell carcinoma could result from differences in
detection methods and the studied populations [28-31].
The present study therefore compared PCR-based detec-
tion of HPV with immunohistochemical expressions of
p16INK4A, EGFR and pEGFR; and the potential value of use
of these biomarkers as indicators of HPV positivity in
selected cases of HIV/AIDS-related SCCC.
Results
Patient’s demographics and histology
Out of the 58 samples evaluated, the ratio of females to
males was 1:1. The age ranged from 23 to 73 years, with
a mean of 41.6 years and median of 39 years. Fifty six
cases were classified as squamous cell carcinomas and the
remaining two as carcinoma in situ. Tumor site, tumor
size and tumor grades were as shown in Table 1 and
Figure 1a-c.
Expressions of p16INK4A, EGFR and pEGFR
Immunohistochemistry assay was done in all the fifty eight
studied cases, of which Out of the fifty eight cases, thirty
nine (67.2%) were positive for p16INK4A staining, forty
eight cases (82.8%) for EGFR and fifty one cases (87.9%)
showed positivity for p-EGFR (Figure 2a-c).
The patterns of p16INK4A, EGFR and pEGFR expressions
were semi-quantitatively scored for both intensity and
proportion of staining in the cell nucleus, cytoplasm and
membrane as reported previously [32,33]. Intensity of the
staining were scored as 0 (no staining), 1 (weak positivity),
2 (moderate positivity), or 3 (strong positivity). The pro-
portions of the staining were also evaluated and scored as
0 (1%-10% of cells stained), 1 (11%-50%), 2 (51%-80%) or
3 (81%-100%). Sections scored as 0 or 1 for intensity was
defined as negative; whereas those scored 2 or 3 were
defined as positive.
HPV 16 is the predominant genotype in AIDS- related
SCCC
From the forty cases where DNA was extracted, four cases
(10%) showed positivity for HPV 16 genotype, and no
Table 1 n = 58
Total %
Age
<50 years 9 15.5
>50 years 42 72.4
Unknown 7 12.1
Sex
Male 29 50%
Female 29 50%
Tumor site
Right orbit/eye/conjunctiva 22 37.9
Left orbit/eye/conjunctiva 24 41.4
Orbit/eye/conjunctiva 12 20.7
Tumor size
<2 cm 36 62.1
2-5 cm 6 10.3
>5 cm 15 25.9
Unknown 1 1.7
Tumor grade
I 29 50
II 21 36.2
III 8 13.8
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with other studies that have documented detection ranges
from 8-10% of high risk HPV in head and neck squamous
cell carcinomas, this low rate of detection suggests that
other mechanisms could underlie pathogenesis of HIV/
AIDS-related squamous cell carcinoma of conjunctiva
independently from the active role of high risk HPV.Figure 1 Haematoxylin and eosin staining. a. Grade I, SCCC X 10
Neoplasm comprising of infiltrating cords of mild to moderatelyCorrelations of HPV detection with p16INK4A, EGFR
expressions
For the cases in which high risk HPV were positive, statis-
tical significant association was found between HPV detec-
tion and p16INK4 expressions, p = 0.000, at 99% confidence
interval and EGFR expression, p = 0.028, at 95% C.I, but
not with pEGFR.pleomorphic malignant squamous cells and of keratin pearls,
interspersed with a chronic inflammatory cell infiltrate). b. Grade II
SCCC X 10 (Neoplasm comprising of infiltrating cords of moderately
pleomorphic malignant squamous cells). c. Grade III SCCC X 20
(Neoplasm disposed in a diffuse architecture, comprising of
moderately to markedly pleomorphic malignant squamous cells).Discussion
A causal relationship between the epidemic of HIV/AIDS
in the Sub-Saharan region and increased incidence of
squamous cell carcinoma of conjunctiva (SCCC) has been
hypothesized, with the prevalence of the neoplasm re-
ported in Kenya alone to be 8% [34,35]. Although immune
suppression has been known to play a critical role in the
pathogenesis, a number of epidemiological studies have
postulated other etiological agents for the development of
squamous cell carcinoma of conjunctiva, such as ultraviolet(UV) light, history of pterygium, and high risk human
papillomavirus infection (HPV) [36-39].
Detection of high risk HPV associated with squamous
cell carcinoma has, however, been controversial, with dif-
ferent authors reporting varied percentages of positivity
Figure 2 a1 (X20) and a2 (X40). Staining for P16INK4A in majority of the neoplastic cells showed intense nuclear staining, which reflects the
functional role of p16 in control of cell cycle prior to the S-phase. In some cells, cytoplasmic positivity appeared prominent. b1 (X20) and b2
(X40). EGFR staining was observed to be brown membrane and cytoplasmic, uniformly distributed in all the squamous epithelial cells. c1 (X10)
and c2 (X20). Staining for pEGFR showed complete brown membrane and cytoplasmic reaction in all epithelial tumors cells.
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ous techniques currently in use, ranging from consensus
and type-specific end-point PCR methods followed with
sequencing, real-time PCR assays for quantification of viral
load, in-situ hybridization, detection of serum antibodies
directed against HPV epitopes, to immunohistochemical
detection of surrogate biomarkers such as p16INK4A, a cyc-
lin dependent kinase inhibitor protein [42-45]. In our study,
a prevalence of 10% of high risk HPV 16 genotype detec-
tion was realized, which is consistent with the findings of
other studies. Many infectious oncogenic viruses yet to be
discovered can use the same mechanism as of high riskHPV in a state of immunosuppression, but the low
prevalence in our study could also be a factor attributed
to poor tissue processing and thus DNA degradation in
a number of the studied cases.
A number of studies have therefore demonstrated that
p16INK4A protein over-expression may serve as a surro-
gate biomarker for biologically and clinically relevant
high risk HPV infection in squamous cell carcinoma of
the conjunctiva, as well as squamous cell carcinoma and
glandular epithelial dysplasia of the uterine cervix [44,45].
Besides, over expression of p16INK4A has also been shown
to correlate with the degree and behavioral characteristics
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[46,47].
In addition to over expression of p16INK4A as potential
surrogate marker of HPV-derived squamous cell carcin-
omas, the development of SCCC in HIV positive patients
has been documented to involve activation of epidermal
growth factor receptor (EGFR) and its phosphorylated
form (p-EGFR) [48-50]. The relationship between HPV
status and levels of EGFR protein expression with clinical
outcome has been reported in several studies, indicating
that the best outcomes are observed in patients with
HPV-positive tumors with low EGFR expression [50-52].
However, an inverse relationship between HPV status and
EGFR gene amplification has also been reported.
Several studies have discussed about the optimal method
for determining HPV status on FFPE tumor sections
(5, 34, 35), and in the current study, we evaluated im-
munohistochemical expressions of p16INKA, EGFR and
p-EGFR IHC as markers of HPV status and utilized
HPV PCR in a subset of cases to correlate the results.
Immunohistochemistry was performed in all the fifty
eight studied cases, and semi-quantitative scores of the
bio-markers enumerated. However, 18 cases were excluded
from HPV detection by PCR technique, followed with
sequencing, because tumor tissue was either inadequate
or had extensive DNA degradation due to poor tissue
processing. A prevalence of 10% of high risk HPV 16
genotype detection was realized, which is consistent with
the findings of other studies. However, the low prevalence
of HPV could be associated with poor tissue processing.
In this study p16INK4A expression in the epithelium was
characterized by variable, weak to strong, diffuse nuclear
and cytoplasmic staining. Thirty nine cases (67.2%) were
positive for p16INK4A staining and showed significant statis-
tical correlation between HPV positivity and p16INK4A ex-
pression (correlation coefficient -0.502, p = 0.000, at 99%
confidence interval (C.I)). This was in agreement with
similar findings from other authors who demonstrated
that p16INK4A expression was significantly associated with
the presence of HPV-16 [20].
The expression of EGFR and its activated form, p-EGFR,
were also independently enumerated in all of the fifty-eight
cases, from which the results demonstrated that 82.8% of
the cases expressed EGFR while 87.9% expressed p-EGFR
as brown membranous and/or cytoplasmic immunostain-
ing, similar to the findings from other studies [53].
Once EGFR is activated into p-EGFR, it undergoes
internalization, resulting in a marked decrease in the
non-activated membrane-bound EGFR [54]. For correl-
ation with HPV positive cases, significant statistical corre-
lations was obtained with EGFR expression (correlation
coefficient -.252, p = .028 at 95% confidence interval). There
was, however, no statistical significant correlation between
HPV status and p-EGFR at both 95% and 99% confidenceIntervals. Equally, no biomarker showed significant statis-
tical correlation with tumor grades.
Therefore, both immunohistochemical assay and PCR-
based techniques showed close agreement in the use of
p16INK4A and EGFR but not p-EGFR as clinically useful
surrogate biomarkers for high risk HPV infection in HIV/
AIDS-associated squamous cell carcinoma of conjunctiva.
Conclusion
Although the exact role played by high risk human papil-
lomavirus in carcinogenesis is not well known, to the best
of our knowledge, this is the first study to show an associ-
ation of high risk HPV infection with p16INK4A and EGFR
over expressions in HIV/AIDS-associated squamous cell
carcinoma of conjunctiva.
Materials and methods
Selection of the study cases
Fifty-eight HIV positive SCCC formalin fixed paraffin
embedded (FFPE) tissue blocks were retrieved from the
archives at pathology department, UON/KNH for analysis.
The criteria for inclusion as HIV positive case included in-
formation from the clinician in the patient’s histological
request form indicating on follow-up at the comprehen-
sive care centre, on HAART treatment, ARV treatment,
immunnosuppression, p24 marker reactive, retrovirus dis-
ease and HIV positive. Sections (4 μm) from the tissue
blocks were stained with hematoxylin and eosin to confirm
the previous diagnoses and establish the tumor grades
according to the WHO guidelines. Ethical approval to
conduct the study was obtained from KNH-ERC.
Immunohistochemistry tests for p16INK4A, EGFR and pEGFR
Immunohistochemistry was performed as described pre-
viously by Russo G, et al. [55]. Briefly, 4 μm sections of
the FFPE tissue blocks were mounted on positively charged
slides and incubated overnight incubation at 65 º C.
Sections were subsequently de-waxed through a series
of xylene, rehydrated in graded series of alcohol (absolute,
90% and 75%), and taken to water. Antigen retrieval was
done by immersing the slides in Tris buffer pH 9 contain-
ing 10 mmol/l EDTA and 15 mmol/l sodium azide (NaN3)
(for p16INK4A) or citrate buffer, pH 6.0 (for EGFR and
pEGFR) and subsequently heated in a microwave at
750 W for 20 minutes, with 5 minutes intervals. All the
slides were then allowed to cool for 20 minutes, and then
rinsed with phosphate buffered saline (PBS) wash buffer.
The sections were quenched in 3% hydrogen peroxide
(H2O2) containing 15 mmol/l sodium azide (NaN3) for
10 minutes to block endogenous peroxidase activity,
followed with a rinse in PBS wash buffer. Ten microlitres
of ready to use primary monoclonal mouse anti-human
antibodies, each of p16INK4A, EGFR (clone EGFR-384-R-
7-CE; Leica, Germany), pEGFR (clone EP774Y, Biocare
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at room temperature, and according to manufacturers’
instructions (Table 1). The sections were rinsed with
wash buffer, followed with incubation in a visualization
reagent for 30 minutes. This was followed with rinsing
and incubation in a substrate-chromogen solution for
10 minutes to facilitate visualization. After the final rinse
with PBS buffer, sections were counterstained with
Mayer’s hematoxylin, dehydrated and mounted. For each
run, normal skin, normal placenta and colon carcinoma
specimens were used as positive controls for p16INK4,
EGFR and pEGFR, respectively.
DNA extraction from tissue blocks
DNA was extracted from 20 sections (5 μm) of the FFPE
tissue blocks using digestion buffer, 50 mM Tris-pH 8.5,
1 mM EDTA, pH 8.0 and 0.5% Tween 20 (Sigma) and
proteinase-K (Roche) at a final concentration of 500 μg/ml.
The lysates were purified using EZ1 DNA Tissue Kit
(Qiagen) and 1 μl of DNA were used in a reaction to
verify DNA integrity, using beta globin and as described
previously in other studies [56-59]. DNA extraction was
successful in forty out of the fifty eight study cases, most
probably due to poor tissue processing that resulted in
DNA degradation.
PCR testing for HPV and genotyping
For the detection of human papillomavirus (HPV) and
the genotypes, PCR was performed, followed with DNA
sequencing on ABI PRISM 310 Genetic Analyzer. The
sequences compared with the GenBank database. In brief,
the PCR reaction was performed in a final volume of
50 μl. Each PCR mixture contained 25 μl of AmpliTaq
Gold PCR Master Mix 2X (Applied Biosystems, NJ USA),
30 pmol of primers (A1 5'- TTGGATCCATGTTAATWS
AGCCWCCAAAATT –3' A2 5'- TTGGATCCTTATCA
WATGCCCAYTGTACCAT –3'), 2 μl of MgCl2 (25 mM)
1 μl of either DNA or water. The cycling conditions were
as follows: 10 minutes at 95°C activation step for Taq
DNA polymerase, followed by 40 cycles each for 40 sec-
onds at 95°C, 50 seconds at 55°C and 40 seconds at 72°C.
The last cycle was followed by a final extension step of
10 minutes at 72°C. The PCR products were analyzed
by electrophoresis on 2% agarose gel stained with eth-
idium bromide using the protocol described by Gleissner
et al. [60].
Positive samples were typed using cut and purified
DNA bands from agarose gel. The DNA were sequenced
with an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems, Weiterstadt, Germany), with the Big Dye
Terminator V1.1 cycle sequencing kit (Applied Biosystems,
NJ, USA) using primer (A1). Sequences were then
compared with the GenBank database as described by
Sgueglia et al. [61].Statistical analysis
Data was then analysed for significant statistical co-
relations using SPSS Version 16. One-tailed p < 0.05 at
95% CI was considered statistically significant.
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